BY PHILIP MADSEN
-
Coloplast shareholders approve huge bonus for management
The investors have actually therefore led the way for the board of supervisors to open up the funds large in the look for a brand-new chief executive officer. ATP calls it an ̶…
-
ATP sharply criticizes Coloplast’s board of directors: “Put mildly, it is a very unusual situation”
Coloplast’s Lars Rasmussen recognizes components of the objection and is sorry for that he and the board did not manage the monitoring adjustments in the firm smoother.
-
Major investor urges Ambu chair to resign from board positions
The chairman refutes having way too many placements, while ATP likewise slams Ambu’s interaction, which, according to the pension plan fund, has actually had an unfavorable e…
-
Despite share price setbacks Ambu heir stands by CEO
After 3 and a fifty percent years as chief executive officer of Ambu, Britt Meelby Jensen has actually been consistently hailed as Ambu’s rescuer; however, for financiers, th…
-
Pension company opposes Coloplast bonus party: “This is a clear boundary for us”
AkademikerPension will certainly elect versus the Coloplast board’s proposition to elevate executive benefits, requiring better openness in the firm’s commission plan a…
-
Coloplast board opens door to bonus feast in new CEO hunt
In order to “bring in and preserve certified ability,” the board of supervisors will certainly make it feasible to offer execs a finalizing perk of as much as 300% of t…
-
Pending Home Sales Slip As Would-Be Buyers Wait For Lower Rates and Economic Clarity
The homes that do market are taking a very long time to discover purchasers, that watch out for high real estate expenses and financial instability. United state pending home sales…
-
Novo Nordisk pledges USD 10bn investment in new deal with Trump
As component of the rates contract with the Trump management introduced Thursday night CET, Novo Nordisk will substantially broaden its manufacturing in the United States.
-
Coloplast falls short of revenue expectations in Q4
The business’s cause Q4 disappoint experts’ earnings assumptions.
-
Ambu raises guidance despite currency and tariff headwinds
The Danish clinical tool business currently anticipates natural profits development of 12-14% by 2025.